Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

Wound Heal Clinical Trial

Official title:

A Phase 1, Double-blind, Single Center, Controlled Study to Evaluate the Safety and Tolerability of FSR Peptide Versus Placebo Following Punch Biopsy in Adult Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04473859
• Other study ID #: ACT1-01
• Status: Completed
• Phase: Phase 1
• Start date: March 6, 2008
• Est. completion date: April 28, 2009

Study information

• Verified date: July 2020
• Source: FirstString Research, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of this study is to test the safety of the study drug (FSR peptide) after a punch biopsy in healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: April 28, 2009
• Est. primary completion date: April 28, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male or female healthy subjects, 18-45 years of age and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.

• Female subjects must have been surgically sterilized at least six months prior to screening. Surgical sterilization procedures must be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. OR: Postmenopausal women must have no regular menstrual bleeding for at least two years prior to inclusion. Menopause was to be confirmed by a plasma 17ß-estradiol concentration of <20 pg/mL and a plasma FSH level of >40 IU/L.

• Normal sitting blood pressure and pulse rate , i.e.: BP: 100 - 140 mm Hg systolic, 50
• 90 mm Hg diastolic and pulse rate: 45 - 100 bpm. Blood pressure and pulse were to be measured after 3 minutes resting in a sitting position.

• Subject body mass index between 18 and 30 kg/m2

• Ability to communicate well with the investigator and comply with the requirements of the entire study.

• The subject has given his written consent to participate in the study.

Exclusion Criteria:

• History of serious adverse reactions or hypersensitivity to any drug.

• Presence or history of any allergy requiring acute or chronic treatment (seasonal) allergic rhinitis which requires no treatment may be tolerated).

• History of alcohol or drug abuse in the last 3 years.

• Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.

• Need of any prescription medication within 14 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study.

• Participation in a clinical trial during the previous 4 weeks, i.e. from completion of the previous trial to the planned first administration of the current trial.

• Loss of 500 ml blood or more during the 3 month period before the study, e.g. as a donor.

• Existence of any surgical or medical condition which might interfere with the distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.

Symptoms of a significant somatic or mental illness in the two week period preceding drug administration.

• History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.

• Positive results from the HIV serology.

• Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation. Serum albumin below 3.5 g/l (Note to File no. 8 states that the correct albumin value is below 35g/l) precludes study inclusion in any case.

• History of serious mental disorders.

• Positive results of the drug screening.

• History or clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurologic or other disease.

• Presence of any active skin pathology including e.g., acne, acute sunburn, inflammatory skin disease.

• Presence of any open wounds or infection on the same arm.

• History of skin disorders e.g. atopic eczema or psoriasis or keloid reaction(s) Any condition that constitutes a contraindication to minor surgical procedures (such as bleeding disorders) or that obliges to the use of prophylactic antibiotics (such as mitral valve prolapse) or other comedications for the performance of minor surgical procedures.

Related Conditions & MeSH terms

• Wound Heal

Intervention

Drug:
• FSR Peptide 20µM
Administered immediately after punch-biopsy and 24 hours after punch biopsy.
• FSR Peptide 50µM
Administered immediately after punch-biopsy and 24 hours after punch biopsy.
• FSR Peptide 100µM
Administered immediately after punch-biopsy and 24 hours after punch biopsy.
• FSR Peptide 200µM
Administered immediately after punch-biopsy and 24 hours after punch biopsy.
• Placebo
Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Locations

Country	Name	City	State
Switzerland	Swiss Pharma Contract Ltd	Allschwil

Sponsors (1)

Lead Sponsor	Collaborator
FirstString Research, Inc.

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of adverse events		Time of consent to day 28
Secondary	Time to healing	The wound was clinically evaluated as healed or not healed.	Up to 28 days
Secondary	Presence of hypertrophic granulation tissue	Clinically assessed as present or not present. To qualify as present, there should be at least 3 mm granulation tissue protruding above the edge of the wound at any point of its perimeter.	Up to 28 days
Secondary	Clinical General Impression scale on the evolution of the wound.	Scale of 1-5: 1- Very bad; 2- Bad; 3- Fair; 4- Good; 5- Very Good	Up to 28 days
Secondary	Wound height	Assessed using the abbreviated Vancouver Scar Scale. The resulting abbreviated score was as follows. Scores are combined to calculate the final score.; Pigmentation 0- Normal. Color that closely resembles the color over the rest of the subject's body; Hypopigmentation; Hyperpigmentation; Vascularity 0- Normal. Color that closely resembles the color over the rest of the subject's body; Pink; Red; Purple	day 28
Secondary	Wound pliability	Assessed using the abbreviated Vancouver Scar Scale. The resulting abbreviated score was as follows. Scores are combined to calculate the final score.; Pigmentation 0- Normal. Color that closely resembles the color over the rest of the subject's body; Hypopigmentation; Hyperpigmentation; Vascularity 0- Normal. Color that closely resembles the color over the rest of the subject's body; Pink; Red; Purple	day 28
Secondary	Histopathological evaluation of the area of the scar tissue	Performed in a punch biopsy taken from the initial wound site at the end of the 28 day evaluation period.	day 28
Secondary	Histopathological evaluation of the epidermal involution	Performed in a punch biopsy taken from the initial wound site at the end of the 28 day evaluation period.	day 28
Secondary	Histopathological evaluation of the rete pegs	Performed in a punch biopsy taken from the initial wound site at the end of the 28 day evaluation period.	day 28
Secondary	Histopathological evaluation of the area of granulation tissue	Performed in a punch biopsy taken from the initial wound site at the end of the 28 day evaluation period.	day 28